Free Access
Volume 86, Number 3, May-June 2006
Page(s) 213 - 226
Published online 31 May 2006
References of Lait 86 213-226
  1. Adlercreutz C.H., Goldin B.R., Gorbach S.L., Hockerstedt K.A., Watanabe S., Hamalainen E.K., Markkanen M.H., Makela T.H., Wahala K.T., Adlercreutz T., Soybean phytoestrogen intake and cancer risk, J. Nutr. 125 (1995) 757S-770S [PubMed].
  2. American Institute of Nutrition, AIN-76A Standards for Nutritional Studies Report. Report of the American Institute of Nutrition Ad Hoc Committee on Standards for Nutritional Studies, Bethesda, Bethesda, USA, 1977.
  3. Association of Official Analytical Chemists, Official Methods of Analysis, 15th edn., Washington DC, USA, 1990.
  4. Aw T.Y., Cellular redox: a modulator of intestinal epithelial cell proliferation, News Physiol. Sci. 18 (2003) 201-204 [PubMed].
  5. Barnes S., Peterson T.G., Coward L., Rationale for the use of genistein - containing soy matrices in chemoprevention trials for breast and prostate cancer, J. Cell. Biochem. 22 (Suppl.) (1995) 181S-185S.
  6. Bennink M.R., Om A.S., Inhibition of colon cancer (CC) by soy phytochemicals but not by soy protein, Fed. Amer. Soc. Exp. Biol. J. 12 (1998) A655.
  7. Bird R.P., Observations and quantification of aberrant crypts in the murine colon treated with a colon carcinogen: preliminary findings, Cancer Lett. 37 (1987) 147-151 [CrossRef] [PubMed].
  8. Bird R.P., Role of aberrant crypt foci in understanding the pathogenesis of colon cancer, Cancer Lett. 93 (1995) 55-71 [CrossRef] [PubMed].
  9. Bird R.P., Aberrant crypt foci to study cancer preventive agents in the colon, in: Hanaucek M., Walaaszek Z. (Eds.), Tumor Marker Protocols, Human Press Inc., New Jersey, USA, 1998, pp. 465-474.
  10. Bird R.P., Good C.K., The significance of aberrant crypt foci in understanding the pathogenesis of colon cancer, Toxicol. Lett. 112/113 (2000) 395-402.
  11. Bligh E.G., Dyer W.J., A rapid method of total lipid extraction and purification, Can. J. Biochem. Physiol. 37 (1959) 911-917 [PubMed].
  12. Bounous G., Whey protein concentrate (WPC) and glutathione modulation in cancer treatment, Anticancer Res. 20 (2000) 4785-4792 [PubMed].
  13. Bounous G., Gold P., The biological activity of undenatured dietary whey proteins: role of glutathione, Clin. Invest. Med. 14 (1991) 296-309 [PubMed].
  14. Bounous G., Kongshavn P.A.L., Differential effect of dietary protein type on B-cell and T-cell immune response in mice, J. Nutr. 115 (1985) 1403-1408 [PubMed].
  15. Bounous G., Létourneau L., Kongshavn P.A.L., Influence of dietary protein type on the immune system of mice, J. Nutr. 113 (1983) 1415-1421 [PubMed].
  16. Bounous G., Papenburg R., Kongshavn P.A.L., Gold P., Fleiszer D., Dietary whey protein inhibits the development of dimethylhydrazine induced malignancy, Clin. Invest. Med. 11 (1988) 213-217 [PubMed].
  17. Bounous G., Batist G., Gold P., Immunoenhancing property of dietary whey protein in mice: role of glutathione, Clin. Invest. Med. 12 (1989) 154-161 [PubMed].
  18. Bounous G., Batist G., Gold P., Whey proteins in cancer prevention, Cancer Lett. 57 (1991) 91-94 [CrossRef] [PubMed].
  19. Bourtourault M., Buleon R., Samperez S., Jouan P., Effet des protéines du lactosérum bovin sur la multiplication de cellules cancéreuses humaines, C.R. Soc. Biol. 185 (1991) 319-323.
  20. Britigan B.E., Serody J.S., Cohen M.S., The role of lactoferrin as an anti-inflammatory molecule, Adv. Exp. Med. Biol. 357 (1994) 143-156 [PubMed].
  21. Cunningham A., Szenberg A., Further improvements in the plaque technique for detecting single antibody forming cells, Immunology 14 (1968) 599-600 [PubMed].
  22. De Luca R.R., Alexandre S.R., Marques T., Souza N.L., Merusse J.L.B., Neves S.P. (Eds.), Manual para técnicas em bioterismo (English translation), 2ª Edição, Colégio Brasileiro de Experimentação Animal, São Paulo, Brazil, 1996.
  23. Gomes F.P., Curso de Estatística Experimental, 10a Edição, Nobel, Piracicaba, São Paulo, Brazil, 1982.
  24. Hakanson A., Zhivotovsky B., Orrenius S., Sabharwal H., Svanborg C., Apoptosis induced by a human milk protein, Proc. Natl. Acad. Sci. USA 92 (1995) 8064-8068 [PubMed].
  25. Lu S.C., Regulation of glutathione synthesis, Curr. Top. Cell. Regul. 36 (2000) 95-116 [PubMed].
  26. McIntosh G.H., Le Leu R.K., The influence of dietary proteins on colon cancer risk, Nutr. Res. 21 (2001) 1053-1066 [CrossRef] [PubMed].
  27. McIntosh G.H., Regester G.Q., Le Leu R.K., Royle P.J., Smithers G.W., Dairy proteins protect againt dimethylhydrazine-induced intestinal cancers in rats, J. Nutr. 125 (1995) 809-816 [PubMed].
  28. McLellan E.A., Bird R.R., Specificity study to evaluate induction of aberrant crypts in murine colons, Cancer Res. 48 (1988) 6183-6186 [PubMed].
  29. Messina M., Bennink M., Soyfoods, isoflavones and risk of colon cancer: a review of the in vitro and in vivo data, Clin. Endocrinol. Metab. 12 (1998) 707-728.
  30. Saville B., A scheme for the colorimetric determination of microgram amounts of thiols, Food Chem. 83 (1958) 670-673.
  31. Sekine K., Ushida Y., Kuhara T., Ligo M., Baba-Toriyama H., Moore M.A., Murakoshi M., Satomi Y., Nishino H., Kakizoe T., Tsuda H., Inhibition of initiation and early stage development of aberrant crypt foci and enhanced natural killer activity in male rats administered bovine lactoferrin concomitantly with azoxymethane, Cancer Lett. 121 (1997) 211-216 [CrossRef] [PubMed].
  32. Sekine K., Ushida Y., Kuhara T., Watanabe E., Nakamura J., Takasuka N., Kim D.J., Asamoto M., Krutovskikh V., Baba-Toriyama H., Ota T., Moore M.A., Masuda M., Sujimoto H., Nishino H., Kakizoe T., Tsuda H., Inhibition of azoxymathane-initiated colon tumor by bovine lactoferrin administration in F344 rats, Jap. J. Cancer Res. 88 (1997) 523-526.
  33. Sgarbieri V.C., The role of dietary energy and macrocomponents of foods in modulating carcinogenesis (an overview), Ciência e Cultura 51 (1999) 104-121.
  34. Spies J.R., Determination of tryptophan in proteins, Anal. Chem. 39 (1967) 1412-1415 [CrossRef] [PubMed].
  35. Stopera S.A., Murphy L.C., Bird R.P., Evidence for a ras gene mutation in azoxymethane-induced colonic aberrant crypts in Sprage-Dawley rats: earliest recognizable precursor lesions of experimental colon cancer, Carcinogenesis 13 (1992) 2081-2085 [PubMed].
  36. Towsend D.M., Tew K.D., Tapiero H., The importance of glutathione in human disease, Biomed. Pharmacother. 57 (2003) 145-155 [CrossRef] [PubMed].
  37. Ushida Y., Sekine K., Kuhara T., Takasuka N., Ligo M., Tsuda H., Inhibitory effect of bovine lactoferrin on intestinal polyposis in the ApcMin Mouse, Cancer Lett. 134 (1998) 141-145 [CrossRef] [PubMed].
  38. Vivona A., Shpitz B., Medline A., Bruce W., Hay K., Ward M., Stern H., Gallinger S., K-ras mutations in aberrant crypt foci, adenomas and adenocarcinomas during azoxymethane-induced colon carcinogenesis, Carcinogenesis 14 (1993) 1777-1781 [PubMed].
  39. Wu G., Fang Y.-Z., Young S., Lupton J.R., Turner N.D., Glutathione metabolism and its implications for health, J. Nutr. 134 (2004) 489-492 [PubMed].
  40. Zinsly P.F., Sgarbieri V.C., Dias N.F.G.P., Jacobucci H.B., Pacheco M.T.B., Baldini V.L.S., Produção piloto de concentrados de proteína de leite bovino: Composição e valor nutritivo, Braz. J. Food Technol. 4 (2001) 1-8.